Page 2 - L Dopa News Today

Once considered uninspiring, dopamines reputation as a neurotransmitter has soared. But that doesnt mean we fully understand the so-called pleasure molecule.

An in-home wireless device records movements and gait speed in Parkinsons, allowing clinicians to monitor disease progression and medication response as accurately as traditional clinic-based tests.

Medical cannabis does not exacerbate disease or neuropsychiatric symptoms in patients with movement disorders, including Huntingtons disease and Parkinsons disease, new research suggests.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies.

The study covered in this summary was published on MedRxiv.org as a preprint and has not yet been peer reviewed.

An experimental drug that combines low-dose extended-release pramipexole and rasagiline showed strong efficacy in early-stage Parkinsons disease — with less sleepiness — in a new phase 3 trial.

A team of researchers has created a bacteria that can produce a steady and consistent source of medicine inside a patient’s gut, suggesting the possibility for genetically edited bacteria to be an efficient Parkinson’s disease treatment.

Although dopamine agonists and dopamine reuptake inhibitors (DRIs) may be effective in treating Parkinsons disease and motor fluctuations not controlled with levodopa, not all DRIs are equal.

Might statins have detrimental effects on long-term motor and cognitive outcomes in patients with Parkinsons disease?

Explore the unique alterations to gut microbiota which have been identified in Parkinsons disease. What significance might they have as a marker of disease progression or therapeutic target?